Developer docs
API playgroundTry for free, no card

Search company profiles

Iasis Pharma

Full company profile

uuid000vqkw

Namestring
Iasis Pharma
Legal namestring
IASIS PHARMACEUTICALS HELLAS S.A.
Websiteurl
iasispharma.com
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Iasis Pharma (legal entity IASIS PHARMACEUTICALS HELLAS S.A.) is a privately held Greek pharmaceutical manufacturer headquartered in Athens, with production operations in Koropi (45,000 m² GMP-certified complex) and Kamatero. Founded in 1985, the company researches, develops, produces, and markets branded generic and proprietary pharmaceutical products across cardiovascular, central nervous system, dermatology, diabetes, gastroenterology, musculoskeletal, respiratory, anti-microbial, and vitamin therapeutic categories, serving Greek pharmacies and hospitals via its dedicated distribution partner Pharma Q and reaching international markets through an International Network division.

The company's product portfolio combines conventional branded generics with differentiated proprietary offerings, including original fixed-dose combinations (Rami-Amlo, Rami-Amlo plus, RosuZet) and unique dosage strengths such as Isotroin 30mg. Its most strategically distinct asset is the Chios Mastic (Pistacia lentiscus var. Chia) product line, developed around a Protected Designation of Origin ingredient and granted EMA Herbal Medicinal Product status in 2015 for functional dyspepsia and skin wound healing. Manufacturing leverages IMA (Italian) effervescent tablet technology, liquid and solid dosage lines, and a GMP-certified research center, supported by R&D partnerships with Harokopio University, the National and Kapodistrian University of Athens, and the Union of Chios Mastic Producers via the HYPER-MASTIC green-extraction research consortium.

Go-to-market relies on enterprise field sales to healthcare professionals, systematic exhibition presence at Panhellenic and international (CPhI) medical congresses, and medical science liaison engagement with specialty societies. Revenue is generated through one-time product sales via pharmacy, hospital, and export channels under Greece's regulated pharmaceutical pricing framework, with no public disclosure of pricing or unit economics. The company's strategic emphasis is on leveraging its EMA-approved herbal platform, proprietary fixed-dose combinations, and manufacturing scale to extend from the Greek domestic base into selected international markets.

Short descriptiontext

Iasis Pharma is a Greek pharmaceutical manufacturer that develops, produces, and markets branded generics and proprietary medicines across multiple therapeutic areas, serving Greek pharmacies and hospitals via distribution partner Pharma Q and exporting internationally through CPhI-sourced partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded generic pharmaceuticals, herbal medicine products, cardiovascular drug formulations, dermatology pharmaceuticals, fixed-dose combinations
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Branded Generic Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Branded Generic Pharmaceuticals
TypeOne Time License
Description

Sale of branded generic pharmaceutical products across multiple therapeutic categories (cardiovascular, CNS, dermatology, diabetes, gastrointestinal, musculoskeletal, respiratory, vitamins, anti-microbials) primarily in the Greek domestic market through pharmacies and hospitals. Products include original combinations and proprietary formulations.

iasispharma.com
2Proprietary Herbal Medicines
TypeOne Time License
Description

Sale of proprietary herbal medicine products based on Chios Mastic (Mastiha var. Chia), including EMA-approved capsules for functional dyspepsia, powder formulation, and topical gel for skin conditions. Sold in Greece and international markets.

iasispharma.com
3Original Proprietary Products
TypeOne Time License
Description

Sale of original fixed-dose combination products (Rami-Amlo, Rami-Amlo plus, RosuZet) and unique dosage strength products (Isotroin 30mg) that are not generic equivalents, commanding premium positioning in the market.

iasispharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Mastiha var. Chia Products
Description

Product line featuring Chios mastic (Pistacia lentiscus var. Chia) including capsules, powder, and cutaneous gel for gastrointestinal and dermatological applications

iasispharma.com
+1 more record
Core offering1 text field

Iasis Pharma researches, develops, manufactures, imports, and markets branded generic and proprietary pharmaceutical products across multiple therapeutic areas, including cardiovascular, dermatology, diabetes, gastroenterology, CNS, musculoskeletal, and respiratory. Its portfolio includes original fixed-dose combinations (RosuZet, Rami-Amlo, Rami-Amlo plus), unique dosage strengths (Isotroin 30mg), and EMA-approved Chios Mastic herbal medicine products (capsules, powder, and cutaneous gel). Manufacturing is performed in GMP-certified facilities in Greece.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • EMA 2015 recognition of Chios Mastic as Herbal Medicine for functional dyspepsia and skin wound healing
+2 more records
Product overview1 text field

Iasis Pharma is a Greek pharmaceutical company (IASIS PHARMACEUTICALS HELLAS S.A.) that manufactures high-quality generic and proprietary pharmaceutical products. The company operates in the pharmaceutical and cosmetics industry with a diverse portfolio covering multiple therapeutic areas including cardiovascular system (RosuZet®, Rami-Amlo®, Rami-Amlo plus®, Licepler®, COVED®), diabetes (Glucofree®, Glucoplus®), dermatology (Isotroin®, Modiwart®, Combi®, Sensibio®, Flusterix®), gastroenterology (Mastiha var. Chia products including caps, powder, and gel formulations), musculoskeletal/anti-inflammatory (ETROZAC®), and nutritional supplements (MAG-IASIS®). The company also produces a wide range of generic medications across therapeutic categories including antibiotics, vitamins, and central nervous system treatments. Iasis Pharma maintains international operations and has received EMA approval for its flagship herbal product, Mastiha var. Chia.

Product and service17 records
1Isotroin®
CategoryDermatology Pharmaceuticals
Description

Isotretinoin soft gel capsules for severe acne treatment resistant to systemic antibiotics and topical therapy, available in 10mg, 20mg, 30mg (unique), and 40mg strengths.

2RosuZet®
CategoryCardiovascular Pharmaceuticals
Description

Original fixed-dose combination of Rosuvastatin and Ezetimibe in film-coated tablets for lipid modification, available in 5/10mg, 10/10mg, 20/10mg, and 40/10mg strengths.

3Rami-Amlo®
CategoryCardiovascular Pharmaceuticals
Description

Original fixed-dose combination of Ramipril and Amlodipine in hard capsules for hypertension treatment, available in 28 capsules with 4 strengths.

4Rami-Amlo plus®
CategoryCardiovascular Pharmaceuticals
Description

Original fixed-dose combination of Ramipril, Amlodipine, and Hydrochlorothiazide for hypertension treatment, available in 30 capsules with wide dosage range.

5Mastiha var. Chia caps®
CategoryGastroenterology Herbal Medicine
Description

Unique herbal medicine containing natural Chios mastic Pistacia lentiscus resin (350mg/capsule) for functional dyspepsia, EMA approved since 2015.

6Mastiha var. Chia Cutaneous Regenerative Gel
CategoryDermatology Herbal Medicine
Description

Regenerative and soothing gel (30ml) for minor skin inflammations and healing of microtraumas, containing 10% lyophilized resin of natural Chios mastic.

7Mastiha var. Chia Powder (Μαστίχα Χίου Σκόνη)
CategoryGastroenterology Herbal Medicine
Description

Chios Mastic powder product in 15 sachets packaging for various therapeutic applications including gastrointestinal indications.

8Glucofree® & Glucoplus®
CategoryDiabetes Pharmaceuticals
Description

Metformin hydrochloride film-coated tablets for Type 2 diabetes treatment; Glucofree (850mg) and Glucoplus (1000mg) in boxes of 60 film-coated tablets.

9MAG-IASIS®
CategoryNutritional Supplements
Description

Magnesium combination product with 1193.57mg Magnesium citrate and 667.56mg Magnesium aspartate (equivalent to 243mg Magnesium) for magnesium deficiency, in 40 effervescent tablets.

10Modiwart®
CategoryDermatology Pharmaceuticals
Description

Imiquimod 12.5mg/sachet immunomodulator for external genital warts, superficial basal cell carcinomas, and actinic keratoses.

11Combi®
CategoryDermatology Pharmaceuticals
Description

Combination of fluprednidene (1mg) and miconazole (20mg) in 50g cream for inflammatory dermatomycoses.

12Etrozac®
CategoryMusculoskeletal Pharmaceuticals
Description

Etoricoxib selective COX-2 inhibitor for relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and inflammation symptoms.

13Licepler®
CategoryCardiovascular Pharmaceuticals
Description

Eplerenone product available in 30 film-coated tablets in 25mg and 50mg strengths for cardiovascular indications.

14COVED®
CategoryOsteoporosis / Bone Health Pharmaceuticals
Description

Alendronic acid 70mg with cholecalciferol 5,600IU for postmenopausal osteoporosis treatment and vitamin D deficiency.

15Sensibio®
CategoryDermatology Pharmaceuticals
Description

Combination of Fusidic Acid (2%) and Betamethasone Valerate (0.1%) in cream form for dermatological conditions, available in 15g and 30g packaging.

16Flusterix®
CategoryDermatology Pharmaceuticals
Description

Antibiotic cream for external use, available in 15g and 30g packaging.

17Zylapour®
CategoryMusculoskeletal Pharmaceuticals
Description

Allopurinol product (xanthine oxidase inhibitor) for gout treatment, available in 100mg x 30 tabs, 100mg x 100 tabs, and 300mg x 30 packages.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Union of Chios Mastic Producers (E.M.X. / E.M.Χ.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

The Union of Chios Mastic Producers collaborates with IASIS PHARMA on the HYPER-MASTIC research project to develop innovative antihypertensive phytotherapeutic products based on Chios Mastic. The union represents producers of the Protected Designation of Origin Chios Mastic ingredient.

iasispharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Academic research partner in the HYPER-MASTIC project, contributing scientific expertise on bioactive natural products and their effects on cardiovascular health. The university brings pharmacological research capabilities to the collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Key academic partner in Chios Mastic research. The Department of Pharmacognosy authored the most updated pharmacological review of Chios Mastic's properties and coordinates the HYPER-MASTIC project. Also involved in the Competence Center for Natural Products.

4Therapeutic Clinic of the Medical School (Hellenic School)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Clinical research partner in the HYPER-MASTIC project, contributing medical and clinical expertise for the development and testing of Chios Mastic-based antihypertensive products.

iasispharma.com
5Competence Center for Natural Products (ΚΙΦΠ)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

IASIS PHARMA co-founded the Competence Center for Natural Products (ΚΙΦΠ), a Cooperative Innovation Formation with 15 partners from academic and business sectors. Coordinated by the Laboratory of Exploitation of Bioactive Natural Products, Faculty of Pharmacy (NKUA). Focuses on research and innovation in Greek natural product-based pharmaceuticals.

iasispharma.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-09-01
Description

IMA Group, based in Italy, is the world leader in automated pharmaceutical manufacturing equipment design and construction. IASIS PHARMA selected IMA technology for its effervescent tablet production line, achieving top-quality production with extremely high production rates at its Koropi facility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-07-01
Description

IASIS PHARMA maintains active participation in the Chios Mastic Research Center, established in Kallimachia, Chios in summer 2017. The center conducts research on applications of Chios Mastic and collaborates on product development.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Pharma Q is the sales and distribution partner for IASIS PHARMA products in Greece. Dr. Christos Zavos, Gastroenterologist-Hepatologist, presented the Mastiha powder product to Pharma Q sales partners at the new IASIS PHARMA facilities in Koropi.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Established Greek pharmaceutical manufacturer with branded-generic portfolio across multiple therapeutic areas; comparable in domestic Greek market position and portfolio breadth.

TypeDirect peer
Description

European specialty generics and consumer health company with branded-generic portfolio across cardiovascular, dermatology, and CNS — comparable business model of specialty generics with proprietary branded positioning in European markets.

TypeDirect peer
Description

Greek branded-generic manufacturer with portfolio overlap in cardiovascular, CNS, and dermatology, and a similar pattern of proprietary FDC launches in the domestic Greek market.

TypeDirect peer
Description

Greek pharmaceutical manufacturer with overlapping branded-generic and specialty pharma portfolio across cardiovascular, respiratory, and CNS categories, operating its own GMP manufacturing in Greece — the closest scale and model match to IASIS.

5Sandoz (Novartis)
TypeBroad incumbent
Description

Global generics and biosimilars division with deep European presence and overlapping portfolio in cardiovascular, dermatology, and CNS categories; relevant as the broad incumbent defining the competitive context for branded-generic strategies.

TypeBroad incumbent
Description

Global generics leader offering overlapping therapeutic categories including isotretinoin, metformin, and cardiovascular products; relevant as a broad incumbent setting pricing and competition dynamics in categories where IASIS operates.

TypeDirect peer
Description

Greek specialty pharmaceutical company with branded generics, ophthalmics, and proprietary formulations; comparable in mid-sized Greek specialty pharma profile and export orientation.

8Specifar Pharmaceuticals (Aenova Group)
TypeDirect peer
Description

Greek-origin generic pharmaceutical manufacturer now part of Aenova; directly comparable as a Greek-based generic manufacturer with international distribution into regulated European markets.

TypeDirect peer
Description

Greek specialty generics developer with broad therapeutic coverage and strong international footprint; comparable business model as a Greek-origin branded-generic producer with proprietary formulation capabilities.

TypeDirect peer
Description

One of the largest Greek pharmaceutical manufacturers with broad branded-generic portfolio across cardiovascular, CNS, anti-infectives, and dermatology — comparable in therapeutic breadth and Greek market focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iasis Pharma

Branded Generic Pharmaceuticalsiasispharma.com

Iasis Pharma is a Greek pharmaceutical manufacturer that develops, produces, and markets branded generics and proprietary medicines across multiple therapeutic areas, serving Greek pharmacies and hospitals via distribution partner Pharma Q and exporting internationally through CPhI-sourced partnerships.

What Iasis Pharma does

Iasis Pharma (legal entity IASIS PHARMACEUTICALS HELLAS S.A.) is a privately held Greek pharmaceutical manufacturer headquartered in Athens, with production operations in Koropi (45,000 m² GMP-certified complex) and Kamatero. Founded in 1985, the company researches, develops, produces, and markets branded generic and proprietary pharmaceutical products across cardiovascular, central nervous system, dermatology, diabetes, gastroenterology, musculoskeletal, respiratory, anti-microbial, and vitamin therapeutic categories, serving Greek pharmacies and hospitals via its dedicated distribution partner Pharma Q and reaching international markets through an International Network division.

The company's product portfolio combines conventional branded generics with differentiated proprietary offerings, including original fixed-dose combinations (Rami-Amlo, Rami-Amlo plus, RosuZet) and unique dosage strengths such as Isotroin 30mg. Its most strategically distinct asset is the Chios Mastic (Pistacia lentiscus var. Chia) product line, developed around a Protected Designation of Origin ingredient and granted EMA Herbal Medicinal Product status in 2015 for functional dyspepsia and skin wound healing. Manufacturing leverages IMA (Italian) effervescent tablet technology, liquid and solid dosage lines, and a GMP-certified research center, supported by R&D partnerships with Harokopio University, the National and Kapodistrian University of Athens, and the Union of Chios Mastic Producers via the HYPER-MASTIC green-extraction research consortium.

Go-to-market relies on enterprise field sales to healthcare professionals, systematic exhibition presence at Panhellenic and international (CPhI) medical congresses, and medical science liaison engagement with specialty societies. Revenue is generated through one-time product sales via pharmacy, hospital, and export channels under Greece's regulated pharmaceutical pricing framework, with no public disclosure of pricing or unit economics. The company's strategic emphasis is on leveraging its EMA-approved herbal platform, proprietary fixed-dose combinations, and manufacturing scale to extend from the Greek domestic base into selected international markets.

Iasis Pharma firmographics

Firmographics
Name
Iasis Pharma
Legal name
IASIS PHARMACEUTICALS HELLAS S.A.
Website
https://iasispharma.com
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
51–100 employees
Short description
Iasis Pharma is a Greek pharmaceutical manufacturer that develops, produces, and markets branded generics and proprietary medicines across multiple therapeutic areas, serving Greek pharmacies and hospitals via distribution partner Pharma Q and exporting internationally through CPhI-sourced partnerships.
Ownership category
akta.pro rank

Iasis Pharma industry classification

Industry
Product category
Branded Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Branded generic pharmaceuticals
  • Herbal medicine products
  • Cardiovascular drug formulations
  • Dermatology pharmaceuticals
  • Fixed-dose combinations

Where Iasis Pharma is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Offices3 records

Markets served

Iasis Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Branded Generic Pharmaceuticals: Sale of branded generic pharmaceutical products across multiple therapeutic categories (cardiovascular, CNS, dermatology, diabetes, gastrointestinal, musculoskeletal, respiratory, vitamins, anti-microbials) primarily in the Greek domestic market through pharmacies and hospitals. Products include original combinations and proprietary formulations.
  2. Proprietary Herbal Medicines: Sale of proprietary herbal medicine products based on Chios Mastic (Mastiha var. Chia), including EMA-approved capsules for functional dyspepsia, powder formulation, and topical gel for skin conditions. Sold in Greece and international markets.
  3. Original Proprietary Products: Sale of original fixed-dose combination products (Rami-Amlo, Rami-Amlo plus, RosuZet) and unique dosage strength products (Isotroin 30mg) that are not generic equivalents, commanding premium positioning in the market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Iasis Pharma product offering

Product offering

Core offering

Iasis Pharma researches, develops, manufactures, imports, and markets branded generic and proprietary pharmaceutical products across multiple therapeutic areas, including cardiovascular, dermatology, diabetes, gastroenterology, CNS, musculoskeletal, and respiratory. Its portfolio includes original fixed-dose combinations (RosuZet, Rami-Amlo, Rami-Amlo plus), unique dosage strengths (Isotroin 30mg), and EMA-approved Chios Mastic herbal medicine products (capsules, powder, and cutaneous gel). Manufacturing is performed in GMP-certified facilities in Greece.

Product overview

Iasis Pharma is a Greek pharmaceutical company (IASIS PHARMACEUTICALS HELLAS S.A.) that manufactures high-quality generic and proprietary pharmaceutical products. The company operates in the pharmaceutical and cosmetics industry with a diverse portfolio covering multiple therapeutic areas including cardiovascular system (RosuZet®, Rami-Amlo®, Rami-Amlo plus®, Licepler®, COVED®), diabetes (Glucofree®, Glucoplus®), dermatology (Isotroin®, Modiwart®, Combi®, Sensibio®, Flusterix®), gastroenterology (Mastiha var. Chia products including caps, powder, and gel formulations), musculoskeletal/anti-inflammatory (ETROZAC®), and nutritional supplements (MAG-IASIS®). The company also produces a wide range of generic medications across therapeutic categories including antibiotics, vitamins, and central nervous system treatments. Iasis Pharma maintains international operations and has received EMA approval for its flagship herbal product, Mastiha var. Chia.

Differentiator

Problem solved

Functional benefit

Brands

  • Mastiha var. Chia Products: Product line featuring Chios mastic (Pistacia lentiscus var. Chia) including capsules, powder, and cutaneous gel for gastrointestinal and dermatological applications
  • PHARMA Q

Products and services

  • Isotroin® Isotretinoin soft gel capsules for severe acne treatment resistant to systemic antibiotics and topical therapy, available in 10mg, 20mg, 30mg (unique), and 40mg strengths.
  • RosuZet® Original fixed-dose combination of Rosuvastatin and Ezetimibe in film-coated tablets for lipid modification, available in 5/10mg, 10/10mg, 20/10mg, and 40/10mg strengths.
  • Rami-Amlo® Original fixed-dose combination of Ramipril and Amlodipine in hard capsules for hypertension treatment, available in 28 capsules with 4 strengths.
  • Rami-Amlo plus® Original fixed-dose combination of Ramipril, Amlodipine, and Hydrochlorothiazide for hypertension treatment, available in 30 capsules with wide dosage range.
  • Mastiha var. Chia caps® Unique herbal medicine containing natural Chios mastic Pistacia lentiscus resin (350mg/capsule) for functional dyspepsia, EMA approved since 2015.
  • Mastiha var. Chia Cutaneous Regenerative Gel Regenerative and soothing gel (30ml) for minor skin inflammations and healing of microtraumas, containing 10% lyophilized resin of natural Chios mastic.
  • Mastiha var. Chia Powder (Μαστίχα Χίου Σκόνη) Chios Mastic powder product in 15 sachets packaging for various therapeutic applications including gastrointestinal indications.
  • Glucofree® & Glucoplus® Metformin hydrochloride film-coated tablets for Type 2 diabetes treatment; Glucofree (850mg) and Glucoplus (1000mg) in boxes of 60 film-coated tablets.
  • MAG-IASIS® Magnesium combination product with 1193.57mg Magnesium citrate and 667.56mg Magnesium aspartate (equivalent to 243mg Magnesium) for magnesium deficiency, in 40 effervescent tablets.
  • Modiwart® Imiquimod 12.5mg/sachet immunomodulator for external genital warts, superficial basal cell carcinomas, and actinic keratoses.
  • Combi® Combination of fluprednidene (1mg) and miconazole (20mg) in 50g cream for inflammatory dermatomycoses.
  • Etrozac® Etoricoxib selective COX-2 inhibitor for relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and inflammation symptoms.
  • Licepler® Eplerenone product available in 30 film-coated tablets in 25mg and 50mg strengths for cardiovascular indications.
  • COVED® Alendronic acid 70mg with cholecalciferol 5,600IU for postmenopausal osteoporosis treatment and vitamin D deficiency.
  • Sensibio® Combination of Fusidic Acid (2%) and Betamethasone Valerate (0.1%) in cream form for dermatological conditions, available in 15g and 30g packaging.
  • Flusterix® Antibiotic cream for external use, available in 15g and 30g packaging.
  • Zylapour® Allopurinol product (xanthine oxidase inhibitor) for gout treatment, available in 100mg x 30 tabs, 100mg x 100 tabs, and 300mg x 30 packages.

Quantifiable outcome

  • EMA 2015 recognition of Chios Mastic as Herbal Medicine for functional dyspepsia and skin wound healing
  • +2 more outcomes

Companies that use Iasis Pharma

Customer profile

Segments6 records

Ideal customer profiles3 records

Iasis Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Iasis Pharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Union of Chios Mastic Producers (E.M.X. / E.M.Χ.)coreStrategic or Co-development Partner · 1 November 2021The Union of Chios Mastic Producers collaborates with IASIS PHARMA on the HYPER-MASTIC research project to develop innovative antihypertensive phytotherapeutic products based on Chios Mastic. The union represents producers of the Protected Designation of Origin Chios Mastic ingredient.
  • Harokopio University of Athens - Department of Nutrition and DieteticscoreStrategic or Co-development Partner · 1 November 2021Academic research partner in the HYPER-MASTIC project, contributing scientific expertise on bioactive natural products and their effects on cardiovascular health. The university brings pharmacological research capabilities to the collaboration.
  • National and Kapodistrian University of Athens (NKUA) - Faculty of Pharmacy, Department of PharmacognosycoreStrategic or Co-development Partner · 1 November 2021Key academic partner in Chios Mastic research. The Department of Pharmacognosy authored the most updated pharmacological review of Chios Mastic's properties and coordinates the HYPER-MASTIC project. Also involved in the Competence Center for Natural Products.
  • Therapeutic Clinic of the Medical School (Hellenic School)coreStrategic or Co-development Partner · 1 November 2021Clinical research partner in the HYPER-MASTIC project, contributing medical and clinical expertise for the development and testing of Chios Mastic-based antihypertensive products.
  • Competence Center for Natural Products (ΚΙΦΠ)coreStrategic or Co-development Partner · 1 September 2021IASIS PHARMA co-founded the Competence Center for Natural Products (ΚΙΦΠ), a Cooperative Innovation Formation with 15 partners from academic and business sectors. Coordinated by the Laboratory of Exploitation of Bioactive Natural Products, Faculty of Pharmacy (NKUA). Focuses on research and innovation in Greek natural product-based pharmaceuticals.
  • IMA Group (Italy)coreTechnology or Integration · 1 September 2021IMA Group, based in Italy, is the world leader in automated pharmaceutical manufacturing equipment design and construction. IASIS PHARMA selected IMA technology for its effervescent tablet production line, achieving top-quality production with extremely high production rates at its Koropi facility.
  • Chios Mastic Research CentercoreStrategic or Co-development Partner · 1 July 2017IASIS PHARMA maintains active participation in the Chios Mastic Research Center, established in Kallimachia, Chios in summer 2017. The center conducts research on applications of Chios Mastic and collaborates on product development.
  • Pharma QcoreChannel Partner/ Reseller/ DistributorPharma Q is the sales and distribution partner for IASIS PHARMA products in Greece. Dr. Christos Zavos, Gastroenterologist-Hepatologist, presented the Mastiha powder product to Pharma Q sales partners at the new IASIS PHARMA facilities in Koropi.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Iasis Pharma competitors and assessment

Company assessment

Direct peers

  • Vianex: Established Greek pharmaceutical manufacturer with branded-generic portfolio across multiple therapeutic areas; comparable in domestic Greek market position and portfolio breadth.
  • Stada Arzneimittel: European specialty generics and consumer health company with branded-generic portfolio across cardiovascular, dermatology, and CNS — comparable business model of specialty generics with proprietary branded positioning in European markets.
  • Help Pharmaceuticals: Greek branded-generic manufacturer with portfolio overlap in cardiovascular, CNS, and dermatology, and a similar pattern of proprietary FDC launches in the domestic Greek market.
  • Elpen Pharmaceutical: Greek pharmaceutical manufacturer with overlapping branded-generic and specialty pharma portfolio across cardiovascular, respiratory, and CNS categories, operating its own GMP manufacturing in Greece — the closest scale and model match to IASIS.
  • Rafarm: Greek specialty pharmaceutical company with branded generics, ophthalmics, and proprietary formulations; comparable in mid-sized Greek specialty pharma profile and export orientation.
  • Specifar Pharmaceuticals (Aenova Group): Greek-origin generic pharmaceutical manufacturer now part of Aenova; directly comparable as a Greek-based generic manufacturer with international distribution into regulated European markets.
  • Pharmathen: Greek specialty generics developer with broad therapeutic coverage and strong international footprint; comparable business model as a Greek-origin branded-generic producer with proprietary formulation capabilities.
  • Demo Pharmaceutical: One of the largest Greek pharmaceutical manufacturers with broad branded-generic portfolio across cardiovascular, CNS, anti-infectives, and dermatology — comparable in therapeutic breadth and Greek market focus.

Broad incumbents

  • Sandoz (Novartis): Global generics and biosimilars division with deep European presence and overlapping portfolio in cardiovascular, dermatology, and CNS categories; relevant as the broad incumbent defining the competitive context for branded-generic strategies.
  • Teva Pharmaceutical: Global generics leader offering overlapping therapeutic categories including isotretinoin, metformin, and cardiovascular products; relevant as a broad incumbent setting pricing and competition dynamics in categories where IASIS operates.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Iasis Pharma social profiles

Digital presence

Iasis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iasis Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Iasis Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iasis Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iasis Pharma

What does Iasis Pharma do?

Iasis Pharma researches, develops, manufactures, imports, and markets branded generic and proprietary pharmaceutical products across multiple therapeutic areas, including cardiovascular, dermatology, diabetes, gastroenterology, CNS, musculoskeletal, and respiratory. Its portfolio includes original fixed-dose combinations (RosuZet, Rami-Amlo, Rami-Amlo plus), unique dosage strengths (Isotroin 30mg), and EMA-approved Chios Mastic herbal medicine products (capsules, powder, and cutaneous gel). Manufacturing is performed in GMP-certified facilities in Greece.

Is Iasis Pharma a public or private company?

Iasis Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Iasis Pharma founded?

Iasis Pharma was founded in 1985. It employs 51 to 100 people.

Where is Iasis Pharma based?

Iasis Pharma is headquartered in Athens, Greece, in the Europe region.

How does Iasis Pharma make money?

Three revenue lines are on record. Branded Generic Pharmaceuticals are the primary driver. The others are proprietary Herbal Medicines and original Proprietary Products.

Who are Iasis Pharma's main competitors?

Direct peers on record are Vianex, Stada Arzneimittel, Help Pharmaceuticals, Elpen Pharmaceutical, Rafarm, Specifar Pharmaceuticals (Aenova Group), Pharmathen and Demo Pharmaceutical. Broad incumbents are Sandoz (Novartis) and Teva Pharmaceutical.

Does Iasis Pharma have an API?

No public API is recorded for Iasis Pharma.

What industry is Iasis Pharma in?

Iasis Pharma's product category is Branded Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales